GentleGen shines on the "Maker China" arena, reshaping the paradigm of biopharmaceutical R&D with the power of AI4S

Release time:2026-08-28

From August 21 to 22, 2026, the 11th "Maker in China" Jiangsu Province SME Innovation and Entrepreneurship Competition Special Competition concluded in Changzhou. At this sci-tech innovation event gathering nearly a hundred high-quality projects from across the province, GentleGen won the Top 100 Project Excellence Award with a high score of 86.41 for its project "AI+ Automated Biopharmaceutical R&D Dry-Wet Verification Closed-Loop Platform Construction and Industrialization." This honor is not only an authoritative recognition of GentleGen's biotechnology strength, but also signifies that biopharmaceutical R&D is undergoing a profound efficiency revolution in the AI4S (AI for Science) era.

Screenshot of WeChat Work_17878122248341

AI4S Era: From "Finding a Needle in a Haystack" to "Precision Design"

Traditional antibody drug development has long relied on extensive manual experiments and repeated trial and error, resulting in long development cycles, low throughput, and high costs. In the wave of the AI4S era, generative AI can "design antibody sequences from scratch" based on target characteristics and complete virtual screening of hundreds of millions of candidate molecules in a short time. Antibody discovery is moving from random screening like "finding a needle in a haystack" to a new stage of intelligence and precision.

Screenshot of WeChat Work_17878122612350

GentleGen is a pioneer in this transformation, focusing on automation and intelligent biotechnology, dedicated to providing life science laboratories with comprehensive solutions from individual scenarios to production lines. Relying on its independently developed GentSynExp 3.0 G-Lab fully automated platform, GentleGen has taken the lead in building a dry-wet closed-loop system covering three frontier areas: antibody drugs, oligonucleotide drugs, and synthetic biology—"AI design—automated synthesis—rapid validation—data return." A large-scale intelligent automated robot platform has been built and put into operation.

Wet and dry closed loop: Bringing AI-designed antibodies into reality

In the "AI + Automated Biopharmaceutical R&D Dry-Wet Verification Closed-Loop Platform" project, GentleGen demonstrated strong technical integration capabilities. The platform centers on self-developed automation hardware and AI algorithms, connecting the entire chain from gene design, automated synthesis, cell-free protein expression to high-throughput functional validation. AI completes intelligent antibody sequence design and virtual screening at the "dry" level, while automated experimental platforms achieve 24-hour unmanned production and high-throughput validation at the "wet" level.

Screenshot of WeChat Work_17878122812434

This model directly addresses industry pain points—AI antibody design is easy, but high-throughput verification is difficult. GentleGen's fully automated platform enables one-stop delivery from genes to antibodies, making AI high-throughput screening truly a routine part of the lab. With its advantages in efficient, precise, and automated production, GentleGen's high-end automated biomanufacturing system—integrating gene to protein and antibody—has become the core and major infrastructure for the closed-loop dry-wet validation in the AI+ biomedicine era.

Deeply cultivating AI4S, empowering innovative pharmaceutical companies

GentleGen's innovative value lies not only in the technology itself but also in the domestically produced, independently controlled, high-throughput R&D solutions it provides to the industry. Traditional R&D models heavily relied on manual labor, whereas GentleGen has significantly shortened R&D cycles and reduced overall costs through deep integration of automation and intelligence.

At this "Maker in China" competition, GentleGen won the Top 100 Project Excellence Award with a score of 86.41, marking an important milestone in GentleGen's development journey and a vivid footnote of AI4S empowering the biopharmaceutical industry. In an era of deep integration between AI and life sciences, GentleGen is leading biopharmaceutical R&D toward a smarter, more efficient, and more inclusive future as a pioneer.

Full-process automation makes AI high-throughput screening a routine in the lab

Relying on its independently developed GentSyn-Exp3.0G-Lab fully automated production line, GentleGen has built a one-stop, high-throughput technology platform covering gene design, synthesis, validation, protein expression, and antibody affinity characterization. Traditional R&D models rely heavily on manual validation, but GentleGen has redefined the efficiency and cost of wet experiments through automation.

Cost-performance revolution: High-throughput expression screening greatly reduces the detection cost of individual samples—IgG monoclonal antibody at 48.9 USD/clone, VHH nanobody at 28.9 USD/clone. Previously, the budget only allowed for synthesizing one or two antibodies, but now GentleGen can complete high-throughput screening of dozens of antibodies.

Ready to use: Each antibody comes with 800 μl of antibody supernatant for direct functional validation—eliminating purification steps and skipping intermediate steps, delivering one-stop downstream testing from genes to antibodies.

GentleGen's G-Lab fully automated gene antibody platform will continuously inject strong momentum into your biopharmaceutical innovation projects through cutting-edge automation technology, rapid delivery capabilities, and rigorous safety and quality control! GentleGen can provide related services. For detailed information about related services, please send an email to marketing@gentlegen.com.

联系销售

联系销售助理

联系PM